← Forte Biosciences overview

Forte Biosciences vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Forte Biosciences Inc (FBRX)

Q3 2026
▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

  • argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.

    This is the single new event that explains the period's move and sets the stock's value near the offer price.

  • Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.

    It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.

  • Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.

    It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

July 2026
▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

  • argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.

    This is the single new event that explains the period's move and sets the stock's value near the offer price.

  • Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.

    It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.

  • Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.

    It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

Latest
▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

  • argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.

    This is the single new event that explains the period's move and sets the stock's value near the offer price.

  • Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.

    It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.

  • Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.

    It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketIVWhy